|
|
TechnoVax’s innovation on the core platform technology allows for the creation of polyvalent influenza VLP vaccines bearing protective antigens of two different influenza viruses on the surface of the same VLP. This is a significant advance over the current influenza vaccine production method which requires growing three different viruses in chicken eggs, chemical inactivation (killed vaccine) and blending in the final vaccine formulation.
Unlike the current influenza vaccine production process, polyvalent VLP vaccines are manufactured in a cell culture system and chemical inactivation is not required because the VLP vaccines are not infectious.
TechnoVax’s novel polyvalent VLP vaccines are produced in a single manufacturing step utilizing a new production process, reducing manufacturing time, steps and costs.
|
Presentación en Español